XBIT
- XBiotech Inc.
()
Overview
Company Summary
XBiotech Inc. is a biopharmaceutical company focused on developing innovative antibody therapies to treat serious diseases. The company uses proprietary technology to identify highly specific antibodies that have the potential to address unmet medical needs.
XBiotech's core expertise lies in its ability to isolate and produce therapeutic antibodies from human donors who possess natural immunity to certain diseases. By studying these individuals, XBiotech aims to identify rare antibodies with unique properties that can be developed into effective treatments.
The company's lead product candidate is bermekimab, an antibody targeting interleukin-1 alpha (IL-1A) for the treatment of various inflammatory conditions. IL-1A is a pro-inflammatory cytokine implicated in diseases such as dermatitis, oncology-related conditions, and cardiovascular diseases. XBiotech is conducting clinical trials to assess the safety and efficacy of bermekimab, with promising results reported so far.
XBiotech has also developed an innovative manufacturing process called True Human� technology. It enables the production of therapeutic antibodies without the need for genetic modification or animal reliance. This approach ensures a more natural and potentially safer product for patients.
Additionally, XBiotech has applied its antibody discovery and production platform to identify potential antibody candidates for other diseases, including infectious diseases and immuno-oncology indications. The company continues to explore new applications and collaborations to expand its pipeline of innovative therapies.
In summary, XBiotech Inc. is a biopharmaceutical company that uses its proprietary antibody discovery and manufacturing technologies to develop targeted therapies, with a primary focus on treating inflammatory conditions. Their approach involves identifying naturally occurring antibodies from human donors and advancing them through clinical trials to potentially offer effective and safe treatments for patients.